Search Patents
  • sphingosine 1-phosphate receptor isoform 1
    Patent number: 7611851
    Abstract: A Canis sphingosine-1-phosphate (S1P) receptor isoform 1 (cS1P1), the nucleic acid encoding the cS1P1 receptor, and methods for using the cS1P1 receptor and the nucleic acid encoding the cS1P1 receptor in assays for identifying analytes which modulate activity of the cS1P1 receptor.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: November 3, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Suzanne M. Mandala, Cheryl Meyers, Gan-Ju Maria Shei
  • Canis sphingosine 1-phosphate receptor isoform 5
    Publication number: 20090191578
    Abstract: A Canis sphingosine-1-phosphate (S1P) receptor isoform 5 (cS1P5), the nucleic acid encoding the cS1P5 receptor, and methods for using the cS1P receptor and the nucleic acid encoding the cS1P5 receptor in assays for identifying analytes which modulate activity of the cS1P5 receptor. The assay is useful for identifying analytes for treating or preventing diseases associated with S1P5 activity.
    Type: Application
    Filed: July 22, 2005
    Publication date: July 30, 2009
    Applicant: MERCK & CO., INC
    Inventors: Suzanne M. Mandala, James A. Milligan
  • Vascular endothelial cell growth factor II
    Patent number: 5726152
    Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: March 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas, Jr.
  • Prostaglandin receptor EP2
    Patent number: 5759789
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: June 2, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Mohammed Adam, Lison Bastien, Richard Grygorczyk, Kathleen Metters, Thomas H. Ruchmore, Nicole Sawyer
  • Anti-cancer antibodies with reduced complement fixation
    Patent number: 7432357
    Abstract: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: October 7, 2008
    Assignee: Merck Patent GmbH
    Inventor: Stephen D. Gillies
  • cDNA cloning of inositol monophosphatase
    Patent number: 5710015
    Abstract: The present invention relates to the cloning of novel cDNA sequences encoding human and rat inositol monophosphatase (IMP); to the preparation of IMP enzyme by incorporation of the cDNAs into an expression vector and the expression thereof in recombinant host cells; and to the use of the enzyme thereby obtained in designing and developing medicaments which are inhibitors of human or rat IMP.
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: January 20, 1998
    Assignee: Merck, Sharp & Dohme, Ltd.
    Inventors: George McAllister, Paul John Whiting
  • Modified pseudomonas exotoxin PE.sub.40
    Patent number: 5912322
    Abstract: Psuedomonas exotoxin 40 is modified by deleting or substituting one or more cysteine residues. Such a modified protein may be incorporated into a fusion protein with TGF.alpha.. The resulting fusion protein exhibits altered biological activities from unmodified TGF.alpha.-PE.sub.40, including decreased cell killing activity and increase receptor-binding activity.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: June 15, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark W. Riemen, Steven M. Stirdivant
  • Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
    Patent number: 7700728
    Abstract: The present invention provides novel materials and screening methods for identifying agonists and antagonists of cell receptors. Methods are disclosed for identifying agonists and antagonists using chimeric receptors comprising the extracellular ligand-binding domain of a first receptor fused with the transmembrane and intracellular domains of a second receptor containing an intracellular immunoreceptor tyrosine-based activation motif (ITAM).
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Elizabeth Esther Mary Bates, Estelle Merck, Odette de Bouteiller, Christophe Caux
  • Melanin concentrating hormone receptor chimeric and fusion proteins
    Patent number: 7029878
    Abstract: The present invention features melanin concentrating hormone receptor (MCH-R) chimeric and fusion proteins. MCH-R chimeric proteins comprise an MCH-R polypeptide region made up of at least two or more polypeptide regions characteristic of MCH-R found in different species. MCH-R fusion proteins comprise an MCH-R polypeptide region and a fluorescent protein region.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: April 18, 2006
    Assignee: Merck & Co., Inc.
    Inventor: Donald J. Marsh
  • CSF3R polypeptides and uses thereof
    Patent number: 7871979
    Abstract: The present invention relates to CSF3R polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: January 18, 2011
    Assignee: Merck Serono SA
    Inventors: Melanie Yorke-Smith, Andreas Pigni
  • Human A3 adenosine receptors
    Patent number: 5817760
    Abstract: The invention concerns recombinant human adenosine receptors A1, A2a, A2b and A3 which have been prepared by cDNA cloning and polymerase chain reaction techniques. The invention also concerns expression systems for these receptors and an assay using the expression systems. The recombinant adenosine receptors comprising the invention can be utililized in an assay to identify and evaluate entities that bind to or enhance binding to adenosine receptors.
    Type: Grant
    Filed: March 27, 1996
    Date of Patent: October 6, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Marlene A. Jacobson, Christopher J. Luneau, Robert G. Johnson, Christopher A. Salvatore
  • Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
    Patent number: 7622553
    Abstract: The present invention provides rhesus monkey dickkopf-1 (rhDkk-1) and nucleotide sequences encoding it. Also provided herein are recombinant vectors, and recombinant hosts comprising rhDkk-1-encoding nucleotide sequences. Isolated rhDkk-1 can be used to screen and identify novel osteoanabolic compounds that stimulate bone formation for the treatment of osteoporosis or other disorders characterized by insufficient bone mass.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: November 24, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Shun-ichi Harada, Viera Kasparcova, Helmut Glantschnig
  • Use of Slurp-1 for treating diseases related to acetylcholine receptor dysfunction
    Patent number: 7691808
    Abstract: Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders. Also disclosed are compositions and methods for the treatment or prevention of skin pathologies. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity. Antibodies generated against SLURP-1 and related proteins are also included.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: April 6, 2010
    Assignee: Merck Serono SA
    Inventors: Fabrice Chimienti, Ronald Hogg, Marcel Huber, Daniel Bertrand, Daniel Hohl
  • Estrogen receptor
    Patent number: 6222015
    Abstract: This invention relates to a novel estrogen receptor and to the polynucleotide sequences encoding this receptor. This invention also relates to methods for identifying ligands which bind to this receptor, to the ligands so identified, and to pharmaceutical compositions comprising such ligands. This invention also relates to pharmaceutical compositions useful for treating or preventing estrogen receptor mediated diseases or conditions, such as abnormal bone resorption, cardiovascular diseases, cancer, or central nervous system disorders.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: April 24, 2001
    Assignee: Merck & Co., Inc.
    Inventor: Hilary Wilkinson
  • Methods of identifying modulators of a prostaglandin receptor
    Patent number: 6358694
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: March 19, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • DNA encoding prostaglandin receptor IP
    Patent number: 5516652
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: October 6, 1993
    Date of Patent: May 14, 1996
    Assignee: Merck Frosst Canada Inc.
    Inventors: Mark Abramovitz, Yves Boie, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz
  • Platelet adhesion inhibitor
    Patent number: 5587360
    Abstract: The inhibitor is protein derived leech tissue or leech secretions (for example, from Hirudo medicinalis), which is capable of binding to native collagen, in such a way that substantially no cleavage breakdown products of coilagen molecules occur on SDS-PAGE. The protein substantially inhibits collagen-induced platelet aggregation or adhesion, has a molecular weight of 60-70 kilodaltons in reduced form and has optimum activity at pH 8.0.
    Type: Grant
    Filed: April 9, 1993
    Date of Patent: December 24, 1996
    Assignee: Merck Patent GmbH
    Inventor: Roy T. Sawyer
  • Process for making human papillomavirus virus-like particles with improved properties
    Patent number: 6436402
    Abstract: Human papillomavirus virus-like particles (VLPs) are subjected to various maturation conditions, including incubation at higher temperatures, exposure to soluble metals or thios-oxidation. The resultant matured VLPs are more stable, and can be used to make a vaccine formulation with increased shelf life and higher potency.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: August 20, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Qinjian Zhao, Shilu Wu, Walter Manger, Shishir Gadam
  • Inhibitor of vascular endothelial cell growth factor
    Publication number: 20030120038
    Abstract: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.
    Type: Application
    Filed: March 19, 2002
    Publication date: June 26, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas
  • Protein for inhibiting collagen-stimulated platelet aggregation
    Patent number: 5324715
    Abstract: A protein isolated from crude Haementeria officinalis extract which blocks stimulation of platelet aggregation by collagen. The protein has a molecular weight of approximately 16,000. A method of isolating the protein and using the protein to prevent or delay blood coagulation by blocking the stimulation of platelet aggregation by collagen is also described. The protein is useful in the prevention, prophylaxis, therapy and treatment of thrombotic diseases.
    Type: Grant
    Filed: April 7, 1993
    Date of Patent: June 28, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Thomas M. Connolly, Paul M. Keller